Oregon Department of Corrections
Approved Formulary
Search by name
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
February P&T meeting minutes have been posted.
Oregon Department of Corrections
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Hazardous Drugs
Please review each of these drugs carefully.
abacavir
Handling Guide (Group 2: Non-Antineoplastic)
abacavir-lamiVUDine
Handling Guide (Group 2: Non-Antineoplastic)
abacavir/dolutegravir/lamiVUDine
Handling Guide (Group 2: Non-Antineoplastic)
abacavir/lamiVUDine/zidovudine
Handling Guide (Group 2: Non-Antineoplastic)
abiraterone
Handling Guide (Group 1: Antineoplastic)
acitretin
Handling Guide (Group 3: Reproductive Risk)
anastrazole
Handling Guide (Group 1: Antineoplastic)
azaTHIOprine
Handling Guide (Group 2: Non-Antineoplastic)
bicalutamide
Handling Guide (Group 1: Antineoplastic)
cabergoline
Handling Guide (Group 3: Reproductive Hazard)
capecitabine
Handling Guide (Group 1: Antineoplastic)
carBAMazepine
Handling Guide (Group 2: Non-Antineoplastic)
clonazepam
Handling Guide (Group 3: Reproductive Risk)
colchicine
Handling Guide (Group 3: Reproductive Hazard)
conjugated estrogens
Handling Guide (Group 2: Non-Antineoplastic)
cyclophosphamide
Handling Guide (Group 1: Antineoplastic)
cycloSPORINE
Handling Guide (Group 2: Non-Antineoplastic)
cyclosporine injectable
Handling Guide (Group 2: Non-Antineoplastic)
cycloSPORINE ophthalmic
Handling Guide (Group 2: Non-Antineoplastic)
dabrafenib
Handling Guide (Group 1: Antineoplastic)
degarelix
Handling Guide (Group 1: Antineoplastic)
divalproex sodium
Handling Guide (Group 2: Non-Antineoplastic)
drospirenone-ethinyl estradiol
Handling Guide (Group 2: Non-Antineoplastic)
dutasteride
Handling Guide (Group 3: Reproductive Risk)
entecavir
Handling Guide (Group 2: Non-Antineoplastic)
enzalutamide
Handling Guide (Group 1: Antineoplastic)
estradiol
Handling Guide (Group 2: Non-Antineoplastic)
estradiol injectable
Handling Guide (Group 2: Non-Antineoplastic)
etonogestrel-ethinyl estradiol
Handling Guide (Group 2: Non-Antineoplastic)
finasteride
Handling Guide (Group 3: Reproductive Risk)
fluconazole
Handling Guide (Group 3: Reproductive Risk)
fluorouracil topical
Handling Guide (Group 1: Antineoplastic)
ganciclovir ophthalmic
Handling Guide (Group 2: Non-Antineoplastic)
hydroxyurea
Handling Guide (Group 1: Antineoplastic)
interferon alfa-2b-ribavirin
Handling Guide (Group 3: Reproductive Risk)
leflunomide
Handling Guide (Group 2: Non-Antineoplastic)
lenalidomide
Handling Guide (Group 2: Non-Antineoplastic)
lenvatinib
Handling Guide (Group 1: Antineoplastic)
leuprolide
Handling Guide (Group 1: Antineoplastic)
levonorgestrel-ethinyl estradiol
Handling Guide (Group 2: Non-Antineoplastic)
liraglutide
Handling Guide (Group 2: Non-Antineoplastic)
medroxyPROGESTERone
Handling Guide (Group 2: Non-Antineoplastic)
megestrol
Handling Guide (Group 1: Antineoplastic)
mercaptopurine
Handling Guide (Group 1: Antineoplastic)
methimazole
Handling Guide (Group 2: Non-Antineoplastic)
methotrexate
Handling Guide (Group 1: Antineoplastic)
methylergonovine
Handling Guide (Group 3: Reproductive Risk)
miSOPROStol
Handling Guide (Group 3: Reproductive Risk)
mycophenolate mofetil
Handling Guide (Group 2: Non-Antineoplastic)
nevirapine
Handling Guide (Group 2: Non-Antineoplastic)
norelgestromin-ethinyl estradiol
Handling Guide (Group 2: Non-Antineoplastic)
norethindrone
Handling Guide (Group 2: Non-Antineoplastic)
norethindrone-ethinyl estradiol
Handling Guide (Group 2: Non-Antineoplastic)
norethindrone-ethinyl estradiol-fe
Handling Guide (Group 2: Non-Antineoplastic)
norgestimate-ethinyl estradiol
Handling Guide (Group 2: Non-Antineoplastic)
norgestrel-ethinyl estradiol
Handling Guide (Group 2: Non-Antineoplastic)
OXcarbazepine
Handling Guide (Group 2: Non-Antineoplastic)
palifermin
PARoxetine
Handling Guide (Group 3: Reproductive Risk)
phenytoin
Handling Guide (Group 2: Non-Antineoplastic)
progesterone
Handling Guide (Group 2: Non-Antineoplastic)
ribavirin
Handling Guide (Group 3: Reproductive Risk)
SORAfenib
Handling Guide (Group 1: Antineoplastic)
spironolactone
Handling Guide (Group 2: Non-Antineoplastic)
tacrolimus
Handling Guide (Group 2: Non-Antineoplastic)
tacrolimus topical
Handling Guide (Group 2: Non-Antineoplastic)
tamoxifen
Handling Guide (Group 1: Antineoplastic)
temazepam
Handling Guide (Group 3: Reproductive Risk)
temozolomide
Handling Guide (Group 1: Antineoplastic)
testosterone
Handling Guide (Group 3: Reproductive Risk)
tofacitinib
Handling Guide (Group 2: Non-Antineoplastics)
topiramate
Handling Guide (Group 3: Reproductive Hazard)
trametinib
Handling Guide (Group 1: Antineoplastic)
tretinoin
Handling Guide (Group 1: Antineoplastic)
tretinoin topical
Handling Guide (Group 3: Reproductive Risk)
valproic acid
Handling Guide (Group 3: Reproductive Risk)
voriconazole
Handling Guide (Group 3: Reproductive Hazard)
warfarin
Handling Guide (Group 3: Reproductive Risk)
zidovudine
Handling Guide (Group 2: Non-Antineoplastic)
ziprasidone
Handling Guide (Group 3: Reproductive Risk)
zoledronic acid
Handling Guide (Group 3: Reproductive Hazard)
zonisamide
Handling Guide (Group 3: Reproductive Risk)